CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

GSK said the upfront settlement amount will be recorded as other operating income in its financial results as an adjusting item in the income statement in the third quarter of 2025. The 2025 and ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

GSK said it would receive $370 million as part of a U.S. patent settlement between CureVac and BioNTech related to messenger mRNA-based Covid-19 vaccines.

In early corporate news, GSK wins a payout after settlement is reached in the legal action between partner CureVac and BioNTech on Thursday, while Renewables Infrastructure posts a widened interim ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells ...

People with head and neck cancer in England will be fast-tracked on to a clinical trial for a “potentially transformative” ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

Patients in England with head and neck cancer will be fast-tracked onto a clinical trial for a "potentially transformative" ...